Back to the future! the evolving role of maintenance therapy after hematopoietic stem cell transplantation

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 2, 2014, Pages 154-163

  Hourigan, Christopher S ^a   McCarthy, Philip ^b   De Lima, Marcos ^c  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Hematology malignancy; Immune system; Leukemia; Lymphoma; Residual disease

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ALLOTRANSPLANTATION; AUTOTRANSPLANTATION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOMODULATION; MAINTENANCE THERAPY; MINIMAL RESIDUAL DISEASE; MYELODYSPLASTIC SYNDROME; NATURAL KILLER CELL; RECURRENT DISEASE; RELAPSE; REVIEW; T LYMPHOCYTE;

HEMATOLOGY MALIGNANCY; IMMUNE SYSTEM; LEUKEMIA; LYMPHOMA; RESIDUAL DISEASE;

HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; RECURRENCE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS;

EID: 84893150784     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.11.017     Document Type: Review

References (107)

1. Bornhauser M., Oelschlaegel U., Platzbecker U., et al. Monitoring of donor chimerism in sorted CD34+ peripheral blood cells allows the sensitive detection of imminent relapse after allogeneic stem cell transplantation. Haematologica 2009, 94:1613-1617.
2. Hokland P., Ommen H.B., Nyvold C.G., Roug A.S. Sensitivity of minimal residual disease in acute myeloid leukaemia in first remission-methodologies in relation to their clinical situation. Br J Haematol 2012, 158:569-580.
3. Thol F., Kolking B., Damm F., et al. Next-generation sequencing for minimal residual disease monitoring in acute myeloid leukemia patients with FLT3-ITD or NPM1 mutations. Genes Chromosomes Cancer 2012, 51:689-695.
4. Faham M., Zheng J., Moorhead M., et al. Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia. Blood 2012, 120:5173-5180.
5. Center for International Blood and Marrow Transplant. U.S. Transplant Data by Disease Report, Number of Transplants Reported for MultipleMyeloma from 2008 - 2011. Available at: 2013. http://bloodcell.transplant.hrsa.gov/RESEARCH/Transplant_Data/US_Tx_Data/Data_by_Disease/national.aspx.
6. Hart A.J., Jagasia M.H., Kim A.S., et al. Minimal residual disease in myeloma: are we there yet?. Biol Blood Marrow Transplant 2012, 18:1790-1799.
7. Ludwig H., Milosavljevic D., Zojer N., et al. Immunoglobulin heavy/light chain ratios improve paraprotein detection and monitoring, identify residual disease and correlate with survival in multiple myeloma patients. Leukemia 2013, 27:213-219.
8. Hillengass J., Landgren O. Challenges and opportunities of novel imaging techniques in monoclonal plasma cell disorders: imaging "arly myeloma". Leukemia Lymphoma 2013, 54:1355-1363.
9. Korthals M., Sehnke N., Kronenwett R., et al. Molecular monitoring of minimal residual disease in the peripheral blood of patients with multiple myeloma. Biol Blood Marrow Transplant 2013, 19:1109-1115.
10. Munshi N.C., Anderson K.C. Minimal residual disease in multiple myeloma. JClin Oncol 2013, 31:2523-2526.
11. Puig N., Sarasquete M.E., Balanzategui A., et al. Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry. Leukemia 2013, [Epub ahead of print] PMID: 23860448. 10.1038/eu.2013.217.
12. Putkonen M., Kairisto V., Juvonen V., et al. Depth of response assessed by quantitative ASO-PCR predicts the outcome after stem cell transplantation in multiple myeloma. Eur J Haematol 2010, 85:416-423.
13. Flanders A., Stetler-Stevenson M., Landgren O. Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity. Blood 2013, 122:1088-1089.
14. Rawstron A.C., Child J.A., de Tute R.M., et al. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study. JClin Oncol 2013, 31:2540-2547.
15. Radich J.P. Monitoring response to tyrosine kinase inhibitor therapy, mutational analysis, and new treatment options in chronic myelogenous leukemia. JNatl Compr Canc Netw 2013, 11:663-666.
16. O'Donnell M.R., Tallman M.S., Abboud C.N., et al. Acute Myeloid Leukemia, Version 2.2013. JNatl Compr Canc Netw 2013, 11:1047-1055.
17. Hourigan C.S., Karp J.E. Minimal residual disease in acute myeloid leukaemia. Nat Rev Clin Oncol 2013, 10:460-471.
18. Paietta E. Minimal residual disease in acute myeloid leukemia: coming of age. Hematology Am Soc Hematol Educ Program 2012, 2012:35-42.
19. Bacher U., Talano J.A., Bishop M.R. Monitoring and prevention of relapse after allogeneic hematopoietic cell transplantation for myeloid malignancies. Biol Blood Marrow Transplant 2012, 18:S62-S73.
20. Walter R.B., Buckley S.A., Pagel J.M., et al. Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. Blood 2013, 122:1813-1821.
21. Walter R.B., Gooley T.A., Wood B.L., et al. Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. JClin Oncol 2011, 29:1190-1197.
22. Venditti A., Maurillo L., Buccisano F., et al. Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantation. Leukemia 2003, 17:2178-2182.
23. Rossi G., Carella A.M., Minervini M.M., et al. Minimal residual disease after allogeneic stem cell transplant: a comparison among multiparametric flow cytometry, Wilms tumor 1 expression and chimerism status (Complete chimerism versus Low Level Mixed Chimerism) in acute leukemia. Leuk Lymphoma 2013, 54:2660-2666.
24. Kwon M., Martinez-Laperche C., Infante M., et al. Evaluation of minimal residual disease by real-time quantitative PCR of Wilms' tumor 1 expression in patients with acute myelogenous leukemia after allogeneic stem cell transplantation: correlation with flow cytometry and chimerism. Biol Blood Marrow Transplant 2012, 18:1235-1242.
25. Rubnitz J.E., Inaba H., Dahl G., et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol 2010, 11:543-552.
26. Schroeder T., Czibere A., Platzbecker U., et al. Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation. Leukemia 2013, 27:1229-1235.
27. Yan C.H., Liu D.H., Liu K.Y., et al. Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Blood 2012, 119:3256-3262.
28. Scott B.L., Wells D.A., Loken M.R., et al. Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome. Blood 2008, 112:2681-2686.
29. Lange T., Hubmann M., Burkhardt R., et al. Monitoring of WT1 expression in PB and CD34(+) donor chimerism of BM predicts early relapse in AML and MDS patients after hematopoietic cell transplantation with reduced-intensity conditioning. Leukemia 2011, 25:498-505.
30. Wright J.J., Poplack D.G., Bakhshi A., et al. Gene rearrangements as markers of clonal variation and minimal residual disease in acute lymphoblastic leukemia. JClin Oncol 1987, 5:735-741.
31. Nyvold C., Madsen H.O., Ryder L.P., et al. Precise quantification of minimal residual disease at day 29 allows identification of children with acute lymphoblastic leukemia and an excellent outcome. Blood 2002, 99:1253-1258.
32. Bruggemann M., Schrauder A., Raff T., et al. Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. Leukemia 2010, 24:521-535.
33. Alvarnas J.C., Brown P.A., Aoun P., et al. Acute lymphoblastic leukemia. JNatl Compr Canc Netw 2012, 10:858-914.
34. Richardson S.E., Khan I., Rawstron A., et al. Risk-stratified adoptive cellular therapy following allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukaemia. Br J Haematol 2013, 160:640-648.
35. Bottcher S., Stilgenbauer S., Busch R., et al. Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis. Leukemia 2009, 23:2007-2017.
36. Rawstron A.C., Bottcher S., Letestu R., et al. Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL. Leukemia 2013, 27:142-149.
37. Logan A.C., Zhang B., Narasimhan B., et al. Minimal residual disease quantification using consensus primers and high-throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia. Leukemia 2013, 27:1659-1665.
38. Bruggemann M., Pott C., Ritgen M., Kneba M. Significance of minimal residual disease in lymphoid malignancies. Acta Haematolo 2004, 112:111-119.
39. Radich J.P., Zelenetz A.D., Chan W.C., et al. NCCN task force report: molecular markers in leukemias and lymphomas. JNatl Compr Canc Netw 2009, 7(Suppl 4):S1-34. quiz S35-36.
40. Ladetto M., Lobetti-Bodoni C., Mantoan B., et al. Persistence of minimal residual disease in the bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program. Blood 2013, 122:3759-3766.
41. Andersen N.S., Pedersen L.B., Laurell A., et al. Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma. JClin Oncol 2009, 27:4365-4370.
42. Ding L., Ley T.J., Larson D.E., et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 2012, 481:506-510.
43. Gerber J.M., Smith B.D., Ngwang B., et al. Aclinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemia. Blood 2012, 119:3571-3577.
44. Pozzi S., Geroldi S., Tedone E., et al. Leukaemia relapse after allogeneic transplants for acute myeloid leukaemia: predictive role of WT1 expression. Br J Haematol 2013, 160:503-509.
45. Hokland P., Ommen H.B. Towards individualized follow-up in adult acute myeloid leukemia in remission. Blood 2011, 117:2577-2584.
46. Jourdan E., Boissel N., Chevret S., et al. Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. Blood 2013, 121:2213-2223.
47. Oran B., Popat U., Rondon G., et al. Significance of persistent cytogenetic abnormalities on myeloablative allogeneic stem cell transplantation in first complete remission. Biol Blood Marrow Transplant 2013, 19:214-220.
48. Li X., Chang C., He Q., et al. Cytogenetic response based on revised IPSS cytogenetic risk stratification and minimal residual disease monitoring by FISH in MDS patients treated with low-dose decitabine. Leuk Res 2013, 37:1516-1521.
49. Platzbecker U. Allogeneic Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndromes. Sem Hematol 2012, 49:342-349.
50. Pfeifer H., Wassmann B., Bethge W., et al. Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia. Leukemia 2013, 27:1254-1262.
51. Bottcher S., Hallek M., Ritgen M., Kneba M. The role of minimal residual disease measurements in the therapy for CLL: is it ready for prime time?. Hematol Oncol Clin North Am 2013, 27:267-288.
52. Brenner M.K., Rill D.R., Moen R.C., et al. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 1993, 341:85-86.
53. Stewart A.K., Vescio R., Schiller G., et al. Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial. JClin Oncol 2001, 19:3771-3779.
54. Furman R.R., Grossbard M.L., Johnson J.L., et al. Aphase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254. Leuk Lymphoma 2011, 52:587-596. Cancer Leukemia Group B, Eastern Cooperative Oncology GroupEastern Cooperative Oncology Group. 10.3109/10428194.2010.543714.
55. Gisselbrecht C., Schmitz N., Mounier N., et al. Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of thecollaborative trial in relapsed aggressive lymphoma. JClin Oncol 2012, 30:4462-4469. 10.1200/JCO.2012.41.9416.
56. Pettengell R., Schmitz N., Gisselbrecht C., et al. Rituximab purging and/or maintenance in patients undergoing autologous transplantation forrelapsed follicular lymphoma: a prospective randomized trial fromthe lymphoma working party of the European group for blood and marrow transplantation. JClin Oncol 2013, 31:1624-1630. 10.1200/JCO.2012.47.1862.
57. Thompson J.A., Fisher R.I., Leblanc M., et al. Total body irradiation, etoposide, cyclophosphamide, and autologous peripheral blood stem-cell transplantation followed by randomization to therapy with interleukin-2 versus observation for patients with non-Hodgkin lymphoma: results of a phase 3 randomized trial by the Southwest Oncology Group (SWOG 9438). Blood 2008, 111:4048-4054. 10.1182/blood-2007-09-111708.
58. Bolaños-Meade J., Garrett-Mayer E., Luznik L., et al. Induction of autologous graft-versus-host disease: results of a randomized prospective clinical trial in patients with poor risk lymphoma. Biol Blood Marrow Transplant 2007, 13:1185-1191.
59. Simonsson B., Tötterman T., Hokland P., et al. Roquinimex (Linomide) vs placebo in AML after autologous bone marrow transplantation. Bone Marrow Transplant 2000, 25:1121-1127.
60. Caocci G., Vacca A., Ledda A., et al. Prophylactic and preemptive therapy with dasatinib after hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. Biol Blood Marrow Transplant 2012, 18:652-654. 10.1016/j.bbmt.2011.12.587.
61. Wetzler M., Watson D., Stock W., et al. Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation - results of CALGB Study 10001 (Alliance). Haematologica. J Natl Compr Canc Netw 2013, 11:35-42.
62. McCarthy P.L. Part I: the role of maintenance therapy in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation. JNatl Compr Canc Netw 2013, 11:35-42. Review.
63. Attal M., Harousseau J.L., Leyvraz S., et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 2006, 108:3289-3294.
64. Barlogie B., Pineda-Roman M., van Rhee F., et al. Thalidomide arm of total therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. Blood 2008, 112:3115-3121.
65. Lokhorst H.M., van der Holt B., Zweegman S., et al. Arandomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. Blood 2010, 115:1113-1120.
66. Morgan G.J., Davies F.E., Gregory W.M., et al. Long-term follow-up of MRC Myeloma IX Trial: survival outcomes with bisphosphonate and thalidomide treatment. Clin Cancer Res 2013, 19:6030-6038.
67. Spencer A., Prince H.M., Roberts A.W., et al. Consolidation therapy with low dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. JClin Oncol 2009, 27:1788-1793.
68. Krishnan A., Pasquini M.C., Logan B., et al. Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol 2011, 12:1195-1203.
69. Maiolino A., Hungria V.T., Garnica M., et al. Thalidomide plus dexamethasone as a maintenance therapy after autologous hematopoietic stem cell transplantation improves progression-free survival in multiple myeloma. Am J Hematol 2012, 87:948-952. Brazilian Multiple Myeloma Study Group (BMMSG/GEMOH). 10.1002/ajh.23274.
70. Stewart A.K., Trudel S., Bahlis N.J., et al. Arandomized phase III trial of thalidomide and prednisone as maintenance therapy following autologous stem cell transplantation (ASCT) in patients with multiple myeloma (MM) with a quality of life assessment: NCIC CTG MY.10 Trial. Blood 2013, 121:1517-1523.
71. McCarthy P.L., Owzar K., Hofmeister C.C., et al. Lenalidomide after stem-cell transplantation for multiple myeloma. NEngl J Med 2012, 366:1770-1781.
72. Attal M., Lauwers-Cances V., Marit G., et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. NEngl J Med 2012, 366:1782-1791.
73. Boccadoro M., Cavallo F., Gay F., et al. Melphalan/prednisone/lenalidomide (MPR) versus high-dose melphalan and autologous transplantation (MEL200) plus lenalidomide maintenance or no maintenance in newly diagnosed multiple myeloma (MM) patients. JClin Oncol 2013, (suppl):8509a. [abstract 8509].
74. Sonneveld P., Schmidt-Wolf I.G., van der Holt B., et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial. JClin Oncol 2012, 30:2946-2955.
75. Cavo M., Pantani L., Petrucci M.T., et al. GIMEMA (Gruppo Italiano Malattie Ematologiche dell'Adulto) Italian Myeloma Network. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood 2012, 120:9-19.
76. Mellqvist U.H., Gimsing P., Hjertner O., et al. Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial. Blood 2013, 121:4647-4654. Nordic Myeloma Study Group.
77. Quach H., Ritchie D., Stewart A.K., et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia 2010, 24:22-32. 10.1038/leu.2009.236.
78. Shanafelt T.D., Ramsay A.G., Zent C.S., et al. Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL). Blood 2013, 121:4137-4141. 10.1182/blood-2012-12-470005.
79. Lonial S., Vij R., Harousseau J.L., et al. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. JClin Oncol 2012, 30:1953-1959. 10.1200/JCO.2011.37.2649.
80. Wang M., Fayad L., Wagner-Bartak N., et al. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol 2012, 13:716-723. 10.1016/S1470-2045(12)70200-0.
81. Younes A., Bartlett N.L., Leonard J.P., et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. NEngl J Med 2010, 363:1812-1821. 10.1056/NEJMoa1002965.
82. Rytting M., Triche L., Thomas D., et al. Initial experience with CMC-544 (inotuzumab ozogamicin) in pediatric patients with relapsed B-cell acute lymphoblastic leukemia. Pediatr Blood Cancer 2013 Sep 2, [Epub ahead of print]. 10.1002/pbc.24721.
83. O'Hear C., Inaba H., Pounds S., et al. Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia. Cancer 2013 Sep 4, [Epub ahead of print]. 10.1002/cncr.28334.
84. Topp M.S., Kufer P., Gökbuget N., et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. JClin Oncol 2011, 29:2493-2498. 10.1200/JCO.2010.32.7270.
85. Kochenderfer J.N., Wilson W.H., Janik J.E., et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 2010, 116:4099-4102.
86. Brentjens R.J., Rivière I., Park J.H., et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 2011, 118:4817-4828.
87. Porter D.L., Levine B.L., Kalos M., et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. NEngl J Med 2011, 365:725-733. 10.1056/NEJMoa1103849.
88. Grupp S.A., Kalos M., Barrett D., et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. NEngl J Med 2013, 368:1509-1518. 10.1056/NEJMoa1215134.
89. Ritchie D.S., Neeson P.J., Khot A., et al. Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia. Mol Ther 2013, 21:2122-2129. 10.1038/mt.2013.154.
90. Bollard C.M., Gottschalk S., Leen A.M., et al. Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood 2007, 110:2838-2845.
91. Maus M.V., Haas A.R., Beatty G.L., et al. Tcells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol Res 2013, 1:26-31.
92. Linette G.P., Stadtmauer E.A., Maus M.V., et al. Cardiovascular toxicity andtitin cross-reactivity of affinity-enhanced T cells in myeloma andmelanoma. Blood 2013, 122:863-871. 10.1182/blood-2013-03-490565.
93. Stauss H.J., Morris E.C. Immunotherapy with gene-modified T cells: limiting side effects provides new challenges. Gene Ther 2013, 20:1029-1032. 10.1038/gt.2013.34.
94. Ramsay A.G. Immune checkpoint blockade immunotherapy to activateanti-tumour T-cell immunity. Br J Haematol 2013, 162:313-325. 10.1111/bjh.12380.
95. Armand P., Nagler A., Weller E.A., et al. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. JClin Oncol 2013, 31:4199-4206.
96. Martner A., Thorén F.B., Aurelius J., Hellstrand K. Immunotherapeutic strategies for relapse control in acute myeloid leukemia. Blood Rev 2013, 27:209-216.
97. Avigan D., Hari P., Battiwalla M., et al. Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Part II. autologous transplantation-novel agents and immunomodulatory strategies. Biol Blood Marrow Transplant 2013, 19:1661-1669.
98. Rosenblatt J., Avivi I., Vasir B., et al. Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients. Clin Cancer Res 2013, 19:3640-3648.
99. de Lima M., Porter D.L., Battiwalla M., et al. NIH/NCI 2nd International Workshop on The Biology, Prevention, and Treatment of Relapse After Hematopoietic Stem Cell Transplantation: Report from the Committee on Relapse after Allogeneic Transplantation: Prevention and Treatment. Biol Blood Marrow Transplant 2013, 20:4-13.
100. Bashir Q., William B.M., Garcia-Manero G., de Lima M. Epigenetic therapy in Allogeneic Hematopoietic Stem Cell Transplantation. Rev Bras Hematol Hemoter 2013, 35:126-133.
101. Gress R.E., Miller J.S., Battiwalla M., et al. Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Part I. biology of relapse after transplantation. Biol Blood Marrow Transplant 2013, 19:1537-1545.
102. Reddy P., de Lima M., Koreth J. emerging therapies in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2012 Jan, 18(1 Suppl):S125-S131.
103. de Lima M., Giralt S., Thall P.F., et al. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for relapsed AML or MDS: a dose and schedule finding study. Cancer 2010, 116:5420-5431.
104. Choi J., Ritchey J., Prior J.L., et al. Invivo administration of hypomethylating agents mitigate graft-versus host disease without sacrificing graft-versus-leukemia. Blood 2010, 116:129-139.
105. Sánchez-Abarca L.I., Gutierrez-Cosio S., Santamaría C., et al. Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting. Blood 2010, 115:107-121.
106. Goodyear O.C., Dennis M., Jilani N.Y., et al. Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML). Blood 2012, 5:3361-3369.
107. Burchert A., Kroeger N., Huenecke S., et al. Post-transplant maintenance with the deacetylase inhibitor panobinostat in patients with high-risk AML or MDS: results of the phase I part of the PANOBEST trial. Blood 2013, [Abstract].